Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $47

Barclays analyst Glen Santangelo has maintained an Overweight rating on Teva Pharmaceutical Industries (NYSE: TEVA) and raised the price target from $42 to $47. This adjustment reflects a positive outlook for the company in the market.